Triangular face

Toceranib (also known as Palladia) is a tyrosine kinase inhibitor used in the treatment of cancer in dogs. It is specifically used for the treatment of mast cell tumors, which are a type of skin cancer. Toceranib works by blocking the action of certain proteins that are involved in the growth and spread of cancer cells.

Mechanism of Action

Toceranib is a multi-targeted receptor tyrosine kinase inhibitor that has both direct antitumor and antiangiogenic activity. It inhibits the Kit and platelet-derived growth factor receptors (PDGFRs), which are often overexpressed or mutated in many types of cancers.

Uses

Toceranib is used in the treatment of mast cell tumors in dogs. It may also be used in the treatment of other types of cancers in dogs, although this use is less common.

Side Effects

Common side effects of toceranib include diarrhea, decreased appetite, and lethargy. Less common side effects include vomiting, weight loss, and skin changes.

Dosage and Administration

Toceranib is administered orally, usually once every other day. The dose is based on the dog's weight and the specific type of cancer being treated.

Precautions

Toceranib should not be used in dogs with known hypersensitivity to the drug. It should also not be used in dogs with severe kidney or liver disease, or in dogs that are pregnant or lactating.

Interactions

Toceranib may interact with other medications, including other chemotherapy drugs, corticosteroids, and certain antibiotics. It is important to inform the veterinarian of any other medications the dog is taking before starting treatment with toceranib.

References

• Plumb, D. C. (2018). Plumb's Veterinary Drug Handbook (9th ed.). Wiley-Blackwell. ISBN 978-1-119-40068-1.

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia